Multilobated non-hodgkin's lymphoma. A clinicopathologic entity

Baarlen, Joop van; Schuurman, Henk‐Jan; Unnik, J. A. M. van

doi:10.1002/1097-0142(19880401)61:7<1371::aid-cncr2820610716>3.0.co;2-g

Cited by 26 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of cases occur in lymph nodes with 40% in extranodal sites (4) . These cases occur most frequently in the gastrointestinal tract, but may appear in any organ, including the skin, central nervous system (CNS), bone marrow (BM), salivary gland, lung, kidney, and liver (5,6) . Bone marrow involvement is found in 11% to 27% of all cases but rarely infiltrates the peripheral blood (7) .…”

Section: Introductionmentioning

confidence: 99%

“…Immunophenotyping is essential to differentiate it from classic Hodgkin lymphoma (cHL). This variant is rare and presents a worse prognosis (6) .…”

Section: Introductionmentioning

confidence: 99%

“…Cells may take on acohesive growth pattern, such as that found in carcinoma, or a sinusoidal growth pattern. The malignant cells express the CD30(ki-1) antigen and the main differential diagnoses are Hodgkin's lymphoma (HL) and T-cell NHL that express CD30 (6) .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Gouveia¹,

Siqueira²,

Pereira³

2012

Revista Brasileira De Hematologia E Hemoterapia

View full text Add to dashboard Cite

Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year. At Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP, diffuse large B-Cell lymphoma represents 49.7% of all non-Hodgkin lymphoma cases. Initially, the classification of non-Hodgkin lymphoma was based on morphology, but advances in immunology and molecular medicine allowed the introduction of a biological classification for these diseases. As for other cancers, non-Hodgkin lymphoma involves patterns of multifactorial pathogenesis with environmental factors, as well as genetic, occupational and dietary factors, contributing to its development. Multiple lesions involving molecular pathways of B-cell proliferation and differentiation may result in the activation of oncogenes such as the BCL2, BCL6, and MYC genes and the inactivation of tumor suppressor genes such as p53 and INK4, as well as other important transcription factors such as OCT-1 and OCT-2. A dramatic improvement in survival was seen after the recent introduction of the anti-CD20 monoclonal antibody. The association of this antibody to the cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. However, 50% of all diffuse large B-Cell lymphoma patients remain incurable, creating a demand for more research with new advances in treatment. Thus, it is important to know and understand the key factors and molecular pathways involved in the pathogenesis of diffuse large B-Cell lymphoma.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Immunophenotyping is essential to differentiate it from classic Hodgkin lymphoma (cHL). This variant is rare and presents a worse prognosis (6) .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Gouveia¹,

Siqueira²,

Pereira³

2012

Revista Brasileira De Hematologia E Hemoterapia

View full text Add to dashboard Cite

show abstract

“…The results of the immunophenotyping in our case are also unusual. Multilobated NHL was originally described with a T-cell phenotype [4], but most subsequently reported cases have been shown to have a B-cell phenotype [8]. In our patient, however, it was not possible to determine lineage conclusively as the multilobated cells expressed both a surface antigen generally found on B cells (LN2) and a predominantly T-cell surface antigen (MT1).…”

Section: Discussionmentioning

confidence: 75%

Spontaneous remission of multilobated non‐Hodgkin lymphoma

1992

View full text Add to dashboard Cite

A 67-year-old previously well man was admitted with hypercalcemia after a 7-day history of fever, night sweats, and back pain. The blood showed 5% multilobated lymphoid cells. A multilobated non-Hodgkin lymphoma associated with marked reticulin fibrosis was diagnosed on a bone marrow biopsy. During the next 7 days, in the absence of specific therapy, his symptoms disappeared. Three weeks after admission his biochemical abnormalities had resolved and after 9 weeks his bone marrow examination was normal. He remains in clinical and laboratory remission 16 months after presentation.

show abstract

“…Cells may take on a cohesive growth pattern, such as that found in carcinoma, or a sinusoidal growth pattern. The malignant cells express the CD30 (ki-1) antigen and the main differential diagnoses are Hodgkin's lymphoma (HL) and T-cell NHL that express CD30 (6) .…”

Section: Introductionmentioning

confidence: 99%

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Gouveia¹,

Siqueira²,

Pereira³

2012

Revista Brasileira De Hematologia E Hemoterapia

View full text Add to dashboard Cite

Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year. At Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo -HCFMUSP, diffuse large B-Cell lymphoma represents 49.7% of all non-Hodgkin lymphoma cases. Initially, the classification of non-Hodgkin lymphoma was based on morphology, but advances in immunology and molecular medicine allowed the introduction of a biological classification for these diseases. As for other cancers, non-Hodgkin lymphoma involves patterns of multifactorial pathogenesis with environmental factors, as well as genetic, occupational and dietary factors, contributing to its development. Multiple lesions involving molecular pathways of B-cell proliferation and differentiation may result in the activation of oncogenes such as the BCL2, BCL6, and MYC genes and the inactivation of tumor suppressor genes such as p53 and INK4, as well as other important transcription factors such as OCT-1 and OCT-2. A dramatic improvement in survival was seen after the recent introduction of the anti-CD20 monoclonal antibody. The association of this antibody to the cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. However, 50% of all diffuse large B-Cell lymphoma patients remain incurable, creating a demand for more research with new advances in treatment. Thus, it is important to know and understand the key factors and molecular pathways involved in the pathogenesis of diffuse large B-Cell lymphoma.

show abstract

Multilobated non-hodgkin's lymphoma. A clinicopathologic entity

Cited by 26 publications

References 30 publications

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Spontaneous remission of multilobated non‐Hodgkin lymphoma

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Contact Info

Product

Resources

About